Nautilus Biotechnology, Inc.

Nautilus Biotechnology, Inc., identified by SEC CIK 0001808805, filed a Form 10-Q on November 13, 2020, under accession number 0001140361-20-025536, reflecting the company's quarterly reporting obligations during its early public-market lifecycle. Operating in the biotechnology and life sciences sector, Nautilus Biotechnology focuses on proteomics technology aimed at enabling single-molecule protein analysis at scale. The November 2020 quarterly filing falls within the period preceding the company's SPAC-route entry into public markets, situating it within the broader wave of life sciences blank-check transactions that characterized that era. For full filing history, deal structure details, and sponsor information on Nautilus Biotechnology and hundreds of comparable transactions, sign up for complete data access at SpacDesk.